Anti-SIGLEC-15 Monoclonal Antibody

<strong>anti-SIGLEC-15 Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014622_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 20 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8 ¬∞C_x000D_ <strong>Keywords:</strong> CD33 antigen-like 3, CD33 molecule-like 3, CD33L3, HsT1361, sialic acid-binding Ig-like lectin 15, SIGLEC-15_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Choi BH, Choo GY, Kang JH, Lee CY, Park CS. Effect of anti-siglec-f antibody and reactive oxygen species blocking on histamine release in urinary bladder of ovalbumin-treated mice Int Neurourol J. 2012 Sep;16(3):122-5._x000D_ 2: Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy Nat Med. 2019 Apr;25(4):656-666._x000D_ 3: Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy Clin Cancer Res. 2021 Feb 1;27(3):680-688._x000D_ 4: Fan MK, Zhang GC, Chen W, Qi LL, Xie MF, Zhang YY, Wang L, Zhang Q. Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway Front Oncol. 2021 Jul 16;11:710689._x000D_ 5: Angata T. Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases J Biomed Sci. 2020 Jan 3;27(1):10._x000D_ 6: Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, Wei F, Ren X, Yang L. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis Oncoimmunology. 2020 Aug 28;9(1):1807291._x000D_ 7: Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, Wei F, Ren X, Yang L. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis Oncoimmunology. 2020 Aug 28;9(1):1807291._x000D_ 8: Rashid S, Song D, Yuan J, Mullin BH, Xu J. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer J Cell Physiol. 2022 Mar;237(3):1711-1719._x000D_ 9: Huang R, Zheng J, Shao Y, Zhu L, Yang T. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection Prog Biophys Mol Biol. 2023 Jan;177:34-41._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/36105484">10: Li H, Zhu R, Liu X, Zhao K, Hong D. Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway Oxid Med Cell Longev. 2022 Sep 5;2022:3341038. </a>_x000D_ _x000D_ <strong>Products Related to anti-SIGLEC-15 Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>